| 供体CYP3A5和MDR1基因多态性与肝移植术后受体他克莫司的个体化用药相关性研究 |
| |
| 引用本文： | 吕慧怡,范青,张宁,张策,马辉.供体CYP3A5和MDR1基因多态性与肝移植术后受体他克莫司的个体化用药相关性研究[J].中国药学杂志,2011,46(17):1366-1369. |
| |
| 作者姓名： | 吕慧怡 范青 张宁 张策 马辉 |
| |
| 作者单位： | 大连医科大学附属二院药剂科; |
| |
| 基金项目： | 大连医科大学附属二院青年科研基金资助项目(2007-10) |
| |
| 摘 要： | 目的 研究肝移植供体CYP3A5基因MDR1基因多态性与受体术后他克莫司血药浓度/给药剂量的关系。方法 对39例肝移植患者受体术后他克莫司血药浓度检测。特异性等位基因扩增法和聚合酶链反应结合限制性片段长度多态性分析法分别检测供体CYP3A5和MDR1基因型，按基因型分组比较供体基因多态性与受体他克莫司用药关系。结果 39例肝移植患者供体基因型CYP3A5：*3/*3型12例, *1/*3型8例, *1/*1型19例；MDR1：T/T型13例，C/T型18例, C/C型8例。结论 肝移植病人供体的CYP3A5基因多态性与受体他克莫司血药浓度具有相关性。研究CYP3A5供体基因多态性，有利于移植病人术后他克莫司个体化用药方案的制定；但是供体MDR1基因对他克莫司的受体个体化用药影响不大。
|
| 关 键 词： | 肝移植 他克莫司 CYP3A5 MDR1 基因多态性 |
| 收稿时间： | 2011-11-11; |
Association of Donor CYP3A5 and MDR1 Polymorphisms with the Individual Dosage Regimen of Tacrolimus in Chinese Liver Transplantation Recipients |
| |
| L Hui-yi,FAN Qing,ZHANG Ning,ZHANG Ce,MA Hui.Association of Donor CYP3A5 and MDR1 Polymorphisms with the Individual Dosage Regimen of Tacrolimus in Chinese Liver Transplantation Recipients[J].Chinese Pharmaceutical Journal,2011,46(17):1366-1369. |
| |
| Authors: | L Hui-yi FAN Qing ZHANG Ning ZHANG Ce MA Hui |
| |
| Institution: | Lü Hui-yi,FAN Qing,ZHANG Ning,ZHANG Ce,MA Hui(Department of Pharmacy,The Second Affiliated Hospital of Dalian Medical University,Dalian 116027,China) |
| |
| Abstract: | OBJECTIVE To investigate the effect of CYP3A5 and MDR1 polymorphisms on the concentration / dose ratio of tacrolimus in Chinese liver transplant patients.METHODS Thrirty-nine liver transplant patients treated with tacrolimus were enrolled in this study.Allele-specific Polymerase Chain Reaction amplification and restriction fragment length polymorphism analysis were used to detect donor CYP3A5 and MDR1 genotypes.The patients were grouped according to donor genotype.The relationship between gene polymorphism ... |
| |
| Keywords: | liver transplantation tacrolimus CYP3A5 MDR1 polymorphism |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《中国药学杂志》浏览原始摘要信息 |
| 点击此处可从《中国药学杂志》下载免费的PDF全文 |
